HMN 2026: How A novel DNA-based therapy achieves significant increase in overall survival in platinum resistant ovarian cancer

January 23, 2026 HMN 2026: How A novel DNA-based therapy achieves significant increase in overall survival in platinum resistant ovarian cancer This article was originally published in Health Medicine Network In the randomized Phase II trial, Elenagen was administered once weekly via a simple intramuscular injection. In the reporting, researchers supplementing the standard of care (chemotherapy) with Elenagen, have significantly extended overall survival for patients with the deadliest form of ovarian cancer. Credit: International Journal of Gynecological Cancer (2026). DOI: 10.1016/j.ijgc.2025.104456

The release as fetched from its publisher. curelaboncology.com ↗